The Web Ask Dave Taylor


Patient-derived xenografts (PDX) can closely reflect the genetic diversity of human cancer. PDX models can enable faster, more robust testing of tumor response to treatment and targeted therapy for patients, now referred to as co-clinical trials.

CCXR helps build a library of PDX material available to UW, FHCRC, and Children’s scientists. This helps provide a broad potential grant base, and aid in research recruitment

The successful treatment of cancer is increasingly dependent on targeting therapy to specific tumor characteristics.  Giving our scientists access to a broad “library” of tumor types in a living (mouse) model will enable them, for example, to determine which drugs are likely to work best in particular types of cancer patients, including whether specific sequences or combinations of drugs show more potential than a single drug alone, without having to expose patients to potentially ineffective and toxic drugs.  Having a number of mice with identical tumors can also accelerate research progress by enabling researchers to test several different therapeutic approaches simultaneously.  Building a repository representing a wide array of cancer types can enable research to proceed, even in the absence of access to patients with those particular types of cancer.


Figure provided by The Jackson Laboratory


Seattle Cancer Consortium Partner Institutions:

Seattle Children's .